Axsome and Vertex Stock
Axsome stock (NASDAQ:AXSM) impressed investors this year, rising more than 80% through August. Investors applauded Axsome’s initial moves toward product launch. The biotech firm has given up a significant portion of its gain, yet it continues to defy the bear market.
Don’t worry if you missed out on that significant shift. Other stocks may benefit from the enthusiasm around new items. And one, in particular, is the ideal investment to purchase and keep. Vertex Pharmaceuticals stock (NASDAQ:VRTX) is the company I’m referring to. Let us investigate why.
Vertex Stock: Cystic Fibrosis Leadership
Vertex is well recognized as a pioneer in cystic fibrosis (CF) therapy. The firm offers four CF medicines, the most recent of which is generating blockbuster income. Last year, Trikafta produced more than $5.6 billion in product sales. This resulted in a $2.3 billion profit.
Vertex has the potential to maintain its top position until at least the late 2030s. This is thanks to Trikafta and a contender in phase 3 development. This contender has a good chance of beating Trikafta. Its dose, for example, is once a day rather than twice daily.
However, another therapy area might be driving Vertex’s stock (NASDAQ:VRTX) next round of market growth. Vertex is in the midst of presenting its blood disease candidate to authorities. It plans to finish submissions in the United Kingdom and Europe by the end of the year and to finish its submission in the United States in the first quarter of next year.
What Distinguishes This Candidate?
Exa-cel is a one-time curative therapy for beta-thalassemia and sickle cell disease that was developed in collaboration with CRISPR Therapeutics. Treatment options for these illnesses are currently limited. And these are ailments that last a person’s whole life. So the prospect of a cure is exciting.
Exa-cel might become a blockbuster for Vertex if it is authorized and physicians prescribe it to their patients. Vertex has assumed 60% of the program’s expenditures in exchange for 60% of the earnings. If everything goes as planned, exa-cel may boost Vertex’s billion-dollar revenue, resulting in share price improvements.
How Much Has the Stock Progressed?
Vertex stock (NASDAQ:VRTX) had a difficult spell from late 2020 until last year. The business disclosed the failure of two clinical trials in its alpha-1 antitrypsin-deficient program. Investors were particularly concerned about Vertex’s potential to grow outside the CF market. However, the stock recovered when the business spoke more about favorable exa-cel findings.
Vertex stock (NASDAQ:VRTX) has increased by more than 30% this year. This puts it at 23 times trailing-12-month profits. It was worth more than quadruple that in early 2020 when contenders like exa-cel and others provided investors with considerably less visibility.
What Does This All Mean for You as an Investor?
Even if you missed out on the significant movement earlier this year, there is still time to invest in Axsome.
However, you may want to consider investing in Vertex stock right now. The stock hasn’t risen much in response to the exa-cel announcement. Perhaps it will not in the future, either. However, if everything goes well, exa-cel might generate enormous money.
Featured Image- Megapixl @ Designer491
Author Okoro Chinedu 
